

Package leaflet: Information for the user
Dexamethasone phosphate Accord 4 mg/mL solution for injection/infusion
dexamethasone phosphate

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What Dexamethasone phosphate Accord is and what it is used for
2. What you need to know before you use Dexamethasone phosphate Accord
3. How to use Dexamethasone phosphate Accord
4. Possible side effects
5. How to store Dexamethasone phosphate Accord
6. Contents of the pack and other information

1. What Dexamethasone phosphate Accord is and what it is used for

Dexamethasone phosphate is a synthetic glucocorticoid (adrenocortical hormone) with an effect on metabolism, electrolyte balance, and tissue functions.

Dexamethasone phosphate Accord is used to treat diseases that require treatment with glucocorticoids. Depending on their nature and severity these include:

Via systemic use

- Brain swelling, caused by brain tumour, neurosurgical operations, brain abscess, bacterial meningitis.
- Shock following severe injuries, to prevent acute respiratory distress syndrome (ARDS).
- Treatment of coronavirus disease 2019 (COVID-19) in adult and adolescent patients (aged 12 years and older with body weight at least 40 kg) with difficulty in breathing and need of oxygen therapy.
- Severe acute asthma attack.
- Initial treatment of extensive acute severe skin diseases, such as Erythroderma, pemphigus vulgaris, acute eczema.
- Systemic rheumatic diseases (rheumatic diseases that can affect internal organs), such as systemic lupus erythematosus.
- Active rheumatic joint diseases (rheumatoid arthritis) which is severe and progressive, e.g. forms that rapidly lead to destruction of joints and/or if tissue outside the joints is affected.
- Severe infectious diseases with states similar to poisoning (e.g. tuberculosis, typhus; only in addition to corresponding therapy to treat infection).
- Prevention and treatment of vomiting after operations or in case of cytostatic treatment.
- Supportive treatment of malignant tumours as dexamethasone can sometimes be given by injection or infusion into your vein or under the skin (subcutaneously) to relieve certain symptoms including pain, tiredness, weight loss and feeling and being sick.
- Use in adolescents: Paediatric patients (adolescents of 12 years of age or older with body weight at least 40 kg) are recommended to be given 6 mg into a vein once a day for up to 10 days.

Via local use

- Injection into joints: persistent inflammation in one or a few joints after general treatment of chronic inflammatory joint diseases, activated arthrosis, acute forms of humeroscapular periarthritis.
- Infiltration therapy (when strictly indicated): non-bacterial tendovaginitis and bursitis, periarthropathia, insertional tendinopathy.

2. What you need to know before you use Dexamethasone phosphate Accord

You must not be given Dexamethasone phosphate Accord:

- If you are allergic to dexamethasone or any of the other ingredients of this medicine (listed in section 6).

In individual cases, when dexamethasone phosphate is used, severe hypersensitivity reactions (anaphylactic reactions) have been observed, with circulatory failure, heart attack, cardiac arrhythmias, breathlessness (bronchospasms), and/or a fall or rise in blood pressure.

If you have an infection affecting the whole body, including one which could have been caused by a fungus (e.g. thrush), which is not being treated with antibiotics or appropriate antimicrobial treatment.

Injections into a joint may not be given if you have any of the following conditions:

- Infections within, or in an area close, to the joint being treated
- Bacterial joint infections
- Unstable joint
- Bleeding disorders (spontaneous or caused by anticoagulants)
- Calcifications near joints
- Avascular bone necrosis
- Tendon rupture
- Charcot joint

Local infiltration therapy should not be undertaken without prior additional anti-infective treatment when there is an infection in the area. You should not stop taking any other steroid medications unless your doctor has instructed you to do so.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before being given this medicine:

If, during treatment with dexamethasone phosphate, particular physical stress situations occur (accident, operation, birth, etc.), a temporary increase in dose can be required.

Dexamethasone phosphate can mask the signs of an infection and thus hamper the attempt to identify an existing or developing infection. Latent infections can be reactivated.

Treatment with dexamethasone phosphate should be considered only if this is absolutely necessary with other medicines taken at the same time, targeting the pathogens causing the following disease:

- Acute viral infections (hepatitis B, chickenpox, shingles, *Herpes simplex* infections, inflammations of the cornea caused by *Herpes* viruses)
- HBsAg-positive chronic active hepatitis (infectious liver disease)
- Approximately 8 weeks before and up to 2 weeks after immunisations with a live vaccine
- Acute and chronic bacterial infections
- Systemic fungal infections

- Certain diseases caused by parasites (amoebas, worm infections). In patients with suspected or confirmed threadworm infection (*Strongyloides*), Dexamethasone phosphate Accord can lead to activation and large-scale multiplying of the parasites
- Poliomyelitis
- Lymph node disease after tuberculosis immunization
- Tuberculosis in the medical history

Treatment with dexamethasone phosphate should be specifically monitored in patients with pre-existing medical conditions requiring treatment such as:

- Gastrointestinal ulcers
- Bone thinning (osteoporosis)
- Poorly controlled high blood pressure
- Poorly controlled diabetes mellitus
- Mental illnesses (including in the medical history), including suicide risk. Neurological or psychiatric monitoring is recommended.
- Increased intraocular pressure (narrow-angle and wide-angle glaucoma). Ophthalmological monitoring and accompanying therapy are recommended.
- Injuries and ulcers of the cornea. Ophthalmological monitoring and concomitant therapy are recommended.

Treatment with this medicine may cause pheochromocytoma crisis, which can be fatal. Pheochromocytoma is a rare tumor of the adrenal glands. Crisis can occur with following symptoms: headaches, sweating, palpitations and high blood pressure. Contact your doctor immediately if you experience these signs.

If you have or are suspected of having pheochromocytoma (a tumor of the adrenal glands), talk to your doctor before taking Dexamethasone phosphate Accord.”

If blurred vision or other visual disturbances occur, contact your doctor.

Due to the risk of perforation of the intestinal wall, Dexamethasone phosphate Accord may be used only if there are compelling medical reasons and with corresponding monitoring:

- Severe inflammation of the colon (ulcerative colitis) with a risk of perforation, with abscesses, or with purulent inflammations, possibly also without peritonitis
- Inflamed intestinal pouches (diverticulitis)
- After certain intestinal operations (enteroanastomoses) immediately after the operation.

The signs of peritoneal irritation following rupture of a gastrointestinal ulcer can be absent in patients receiving high doses of glucocorticoids. In patients with diabetes mellitus, the glucose level in blood must be checked regularly as an increased need for medicines used to treat diabetes mellitus (insulin, oral antidiabetics) must be taken into account.

Patients with severe hypertension and/or severe heart failure must be monitored carefully, as there is a risk of deterioration.

At high doses, a slowing of the pulse may occur. Severe anaphylactic reactions (overreaction of the immune system) can occur.

The risk of tendon problems, tendonitis, and tendon ruptures is increased when fluoroquinolones (certain antibiotics) and Dexamethasone phosphate Accord are administered together. When treating a certain form of muscular paralysis (*myasthenia gravis*), symptoms may initially worsen.

Immunisations with vaccines from dead pathogens (inactivated vaccines) are generally possible. However, it must be taken into account that the immune response and thus the success of the immunisation can be impaired if higher doses of corticosteroids are used.

In particular, during a long-term treatment with high doses of Dexamethasone phosphate Accord, it is important to ensure sufficient intake of potassium (e.g. vegetables, bananas) and a limited salt intake and to monitor the potassium blood level.

Viral diseases (e.g. measles, chickenpox) can have a particularly severe course in patients being treated with Dexamethasone phosphate Accord. At particular risk are patients with a compromised immune system who have never previously suffered from measles or chickenpox. If these patients have contact with individuals suffering from measles or chickenpox during treatment with Dexamethasone phosphate Accord, they should contact their doctor immediately, who may start preventative treatment.

Tell your doctor if you notice muscle cramping, muscle weakness, confusion, visual loss or disturbances or shortness of breath, in case you suffer from haematological malignancy. Those can be symptoms of tumor lysis syndrome.

For an intravenous administration, the injection should be given slowly over 2-3 minutes. Following a too rapid administration, short and essentially harmless undesirable effects in the form of unpleasant tingling or paraesthesias, lasting up to 3 minutes can occur.

Dexamethasone phosphate Accord is a drug intended for short-term use. However, if it is used over a fairly long period, further warnings and precautions must be taken into account, as considered for drugs containing glucocorticoids that are intended for long-term use.

With local use, possible systemic side effects and interactions must be taken into account. The intraarticular administration of glucocorticoids increases the risk of joint infections. Longer-term and repeated use of glucocorticoids in weight-bearing joints can lead to a deterioration of wear-related lesions due to possible overload of the joint following a reduction in pain or other symptoms.

Children and adolescents

Dexamethasone should not be routinely used in preterm neonates with respiratory problems. In children, Dexamethasone phosphate Accord should be used only if there are compelling medical reasons, due to the risk of growth inhibition/ retardation. Growth must be regularly checked especially if used for a long-term treatment. If dexamethasone is given to a prematurely born baby, monitoring of heart function and structure is needed.

Elderly

In elderly patients, a thorough benefit-risk assessment must be carried out due to the increased risk for unwanted side effects, e.g. osteoporosis.

Other medicines and Dexamethasone phosphate Accord

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is especially important with the following medicines as they may interact with Dexamethasone phosphate Accord.

Other medicines that can influence the effect of Dexamethasone phosphate Accord:

- Medicines that accelerate breakdown in the liver, such as certain sleeping pills (barbiturates), medicines used to treat seizures (phenytoin, carbamazepine, primidone), and certain medicines used to treat tuberculosis (rifampicin) can reduce the corticoid effect.

- Medicines that slow breakdown in the liver, such as certain medicines used to treat fungal diseases (ketoconazole, itraconazole) can increase the effect of corticoids.
- Certain female sex hormones, e.g. to prevent pregnancy (the pill): the effect of Dexamethasone phosphate Accord can be increased.
- Ephedrine (in medicines used to treat hypotension, chronic bronchitis, asthma attacks, and to reduce the swelling of mucous membranes in colds and as a component in appetite suppressants): through accelerated breakdown in the body, the efficacy of Dexamethasone phosphate Accord can be reduced.
- Some medicines for HIV: ritonavir, cobicistat as they may increase the effects of Dexamethasone phosphate Accord and your doctor may wish to monitor you carefully if you are taking these medicines.

Dexamethasone phosphate Accord can influence the effect of other medicines such as:

- Medicines used to strengthen the heart (cardiac glycosides) as due to potassium deficiency Dexamethasone phosphate Accord can increase their effect.
- Medicines that promote loss of salt upon urination (saluretics) or laxatives as Dexamethasone phosphate Accord can increase potassium excretion caused by these medicines.
- Oral antidiabetics and insulin as Dexamethasone phosphate Accord can reduce their antidiabetic effects (not effective in decreasing glucose levels in the blood).
- Medicines used to inhibit blood coagulation (oral anticoagulants, coumarin). Their effect can be weakened or strengthened by Dexamethasone phosphate Accord. Your doctor will decide whether a dose adjustment of the anticoagulant is necessary.
- Medicines used to treat inflammations and rheumatism (salicylates, indomethacin, and other non-steroidal anti-inflammatory drugs) as Dexamethasone phosphate Accord when used at the same time as those medicines can increase the risk of gastric ulcers and gastrointestinal bleeding.
- Non-depolarising muscle relaxants as their muscle-relaxing effect can be prolonged by Dexamethasone phosphate Accord.
- Certain medicines used to increase intraocular pressure (atropine and other anticholinergics) as their effect may be increased by Dexamethasone phosphate Accord.
- Medicines used to treat diseases caused by worms (praziquantel) as Dexamethasone phosphate Accord can reduce their effect.
- Medicines used to treat malaria or rheumatic diseases (chloroquine, hydrochloroquine, mefloquine). There is an increased risk of body muscle or heart muscle diseases (myopathies, cardiomyopathies) when used at the same time as Dexamethasone phosphate Accord.
- Protirelin (TRH, a hormone produced in the diencephalon) as following its administration, Dexamethasone phosphate Accord can reduce the increase in thyroid-stimulating hormone (TSH).
- Medicines used to suppress the body's own immune system (immunosuppressants). When they are used with Dexamethasone phosphate Accord there is an increased susceptibility to infections and worsening of existing infections that may not yet have become symptomatic.
- Ciclosporin (a medicine used to suppress the body's own immune system), as Dexamethasone phosphate Accord can increase the ciclosporin level and thus the risk of seizures.
- Fluoroquinolones, a certain group of antibiotics, can increase the risk of tendon ruptures.

Impact on investigation methods:

Glucocorticoids can suppress skin reactions to allergy tests. Because of the interactions with these drugs, your doctor might have to adjust the dosage of the medication given to you.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before being given this medicine.

The doctor will then decide if the medicine is suitable for you and may carry out extra checks while you are given this medicine. Dexamethasone crosses the placenta. During pregnancy, particularly in the first three months, treatment should take place only after a careful benefit-risk assessment.

When dexamethasone is administered for prolonged periods or repeatedly during pregnancy, there may be an increased risk for growth retardation in the unborn child. If glucocorticoids are used at the end of pregnancy, underactivity of the adrenal cortex can occur, which can necessitate tapering/replacement treatment in the newborn. Newborns babies of mothers who received Dexamethasone phosphate Accord near the end of pregnancy may have low blood sugar levels after birth.

Glucocorticoids, including dexamethasone, are excreted in breast milk. There have been no reports of the infant being harmed, however, if higher doses are necessary, breast-feeding should be discontinued.

Driving and using machines

There is no evidence to date that dexamethasone phosphate reduces the ability to drive or use machines. The same applies to working in a hazardous setting.

Dexamethasone phosphate Accord contains sodium

This medicine contains 1.4 mg sodium (main component of cooking/table salt) in each ml of solution. This is equivalent to 0.07% of the recommended maximum daily dietary intake of sodium for an adult.

3. How to use Dexamethasone phosphate Accord

Your nurse or doctor will give you this medicine.

Your doctor will decide the correct dosage for you and how and when the medicine will be given.

This medicine is a solution for injection into a vein (IV), a muscle (IM) or under the skin (SC) or tissue.

The dosage depends on the indication, severity of symptoms, the patient's individual response and, in case of injection into a joint, the size of the joint.

Dexamethasone phosphate Accord should be given slowly into a vein (over 2-3 minutes). If administration into a vein is not possible, and if circulatory function is unimpaired, Dexamethasone phosphate Accord can also be administered into a muscle. Dexamethasone phosphate Accord can sometimes also be given by injection or continuous infusion under the skin (subcutaneously).

Dexamethasone phosphate Accord can also be administered by way of infiltration or injection into a joint.

The duration of the treatment is determined based on the underlying disease and its course. Your doctor establishes a treatment schedule, which you must adhere to strictly. As soon as a satisfactory treatment result has been achieved, the dose will be reduced to a maintenance dose or ended. Abrupt discontinuation of medicine administered for more than approximately 10 days can lead to the occurrence of acute adrenal cortex failure, so the dose needs to be gradually reduced before discontinuation. In case of underactive adrenal gland or liver cirrhosis, relatively low doses can be sufficient, or dose reduction can be necessary.

For the treatment of Covid-19:

Adult patients are recommended to be given 6 mg IV once a day for up to 10 days.

If you think you have been given more Dexamethasone phosphate Accord than you should or that you have missed a dose

Since the medicine will be given to you by a doctor or nurse, it is unlikely that you will be given too much or that you will miss a dose. If you are concerned, talk to your doctor or nurse.

In general, Dexamethasone phosphate Accord is tolerated in large quantities without complications even during short-term use. There are no special measures necessary. If you observe more severe or unusual side effects in yourself, you should consult your doctor.

If a dose is missed, it can be given later on the same day, and the dose prescribed by your doctor can continue to be given as usual from the next day onwards. If more than one dose is missed, this can lead to a flare-up or deterioration of the disease being treated. You should consult your doctor, who will review the treatment and adjust the dose if necessary.

If you stop using Dexamethasone phosphate Accord

Always follow the dosing schedule prescribed by your doctor. Dexamethasone phosphate Accord may never be discontinued independently, as, in particular, a relatively long treatment can result in suppression of the body's own production of glucocorticoids (underactivity of the adrenal gland). A pronounced physical stress situation without sufficient glucocorticoid production can be life-threatening. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

In short-term treatment with dexamethasone, the risk of side effects is low. The following side effects are possible:

- stomach or duodenal ulcers;
- reduction in the body's defences against infections;
- increased blood sugar level (decrease in glucose tolerance).

The following side effects may occur, which are highly dependent on the dose and duration of therapy and whose frequency is therefore not known (frequency cannot be estimated from the available data):

Infections and infestations:

Masking of infections, occurrence, recurrence, and deterioration of viral, fungal, and bacterial infections and parasitic or opportunistic infections, activation of threadworm infection.

Blood and lymphatic system disorders:

Changes in the blood count (proliferation of white blood cells or all blood cells, reduction in certain white blood cells).

Immune system disorders:

Hypersensitivity reactions (e.g. drug-induced skin rash), severe anaphylactic reactions, such as arrhythmias, bronchospasms (spasms of the smooth bronchial musculature), excessively high or excessively low blood pressure, circulatory collapse, cardiac arrest, weakening of the immune system.

Endocrine disorders:

The development of Cushing's syndrome (typical symptoms include moon face, abdominal obesity, and facial redness), suppression or loss of adrenal cortex function.

Metabolism and nutrition disorders:

Weight gain, increased blood sugar values, diabetes mellitus, increase in blood lipid values (cholesterol and triglycerides), increased sodium level with tissue swelling (oedema), potassium deficiency due to increased potassium excretion (which can lead to cardiac arrhythmias), increase in appetite.

Psychiatric disorders:

Depression, irritation, euphoria, increased drive, psychoses, mania, hallucinations, affect lability, feelings of anxiety, sleep disturbances, risk of suicide.

Nervous system disorders:

Increased pressure inside the skull, occurrence of previously unknown seizures (epilepsy), increased occurrence of seizures in previously diagnosed epilepsy.

Eye disorders:

Increase in intraocular pressure (glaucoma), opacification of the lens (cataract), deterioration in corneal ulcers, increased risk of, or deterioration, of eye inflammations caused by viruses, bacteria, or fungi; deterioration of bacterial inflammations of the cornea, drooping eyelid, dilated pupils, swelling of the conjunctiva, perforation of the sclera, visual disturbances, loss of vision. In rare cases, reversible bulging of the eyeball.

Heart diseases:

Thickening of the heart muscle (hypertrophic cardiomyopathy) in prematurely born babies, that generally return to normal after stopping treatment.

Vascular disorders:

High blood pressure, increase in the risk of arteriosclerosis and thrombosis, inflammation of blood vessels (also as withdrawal syndrome after long-term therapy), increased fragility of blood vessels.

Gastrointestinal disorders:

Stomach and intestinal ulcers, stomach and intestinal bleeds, pancreatitis, stomach symptoms.

Skin and subcutaneous tissue disorders:

Skin stretch marks, thinning of the skin (parchment skin), dilation of blood vessels, a tendency to develop bruising, points or areas of skin bleeding, increased body hair, acne, inflammatory skin lesions in the face, especially around the mouth, nose, and eyes, changes in skin pigmentation.

Musculoskeletal and connective tissues disorders:

Muscle diseases, muscle weakness and muscle loss, and bone thinning (osteoporosis) occur in a dose-dependent fashion and are possible during only short-term use; other forms of bone loss (bone necroses), tendon-related symptoms, tendonitis, tendon ruptures, fat deposits in the spine (epidural lipomatosis), growth inhibition in children. If the dose is reduced too quickly after long-term treatment, withdrawal symptoms can occur, amongst other things, which can manifest in symptoms such as muscle and joint pain.

Reproductive system and breast disorders:

Disturbances in sex hormone secretion (causing irregular menstruation or a halt to menstruation altogether (amenorrhoea), male body hair patterns in women (hirsutism), impotence).

General disorders and administration site conditions:

delayed wound healing.

Local use:

Local irritation and intolerance are possible (sensation of heat, relatively persistent pain). Skin or subcutaneous tissue thinning (atrophy) at the injection site can occur if corticosteroids are not injected carefully into a joint cavity.

If you experience any of the following, **please contact your doctor immediately:**

- gastrointestinal symptoms,
- pain affecting the back, shoulder, or hip,
- mood disorders,
- marked blood sugar fluctuations in diabetic patients.

Please note that it is very important that you do not suddenly stop taking this medicine (even if you are suffering from a side effect) unless your doctor tells you to (see section 2 and 3).

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly

HPRA Pharmacovigilance,

Website: www.hpra.ie.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Dexamethasone phosphate Accord

Keep this medicine out of the sight and reach of children.

Store below 30 °C. Keep the vial in the outer carton in order to protect from light.

Do not use this medicine after the expiry date stated on the label after 'EXP'. The expiry date refers to the last day of that month.

This product is for single use only. Any unused solution should be discarded.

Do not use this medicine if you notice some visible particles in the solution.

Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Dexamethasone phosphate Accord contains

- The active substance is dexamethasone phosphate.

Each 1 mL of solution for injection/infusion contains 4.0 mg of dexamethasone phosphate (as dexamethasone sodium phosphate).

Each 2 mL of solution for injection/infusion contains 8.0 mg of dexamethasone phosphate (as dexamethasone sodium phosphate).

Each 5 mL of solution for injection/infusion contains 20.0 mg of dexamethasone phosphate (as dexamethasone sodium phosphate).

- The other excipients are creatinine disodium edetate, sodium citrate, sodium hydroxide (to adjust the pH), water for injection.

What Dexamethasone phosphate Accord looks like and contents of the pack

Clear, colourless and sterile solution contained in clear glass vial.

1 mL: 2 ml type I clear glass vial with chlorobutyl rubber stopper and aluminum flip off blue seal.

2 mL: 2 ml type I clear glass vial with chlorobutyl rubber stopper and aluminum flip off plain light blue seal.

5 mL: 6 ml type I clear glass vial with chlorobutyl rubber stopper and aluminum flip off plain light blue seal.

Pack sizes

1 x 1 vial

1 x 3 vials

1 x 5 vials

1 x 10 vials

1 x 20 vials

1 x 25 vials

1 x 50 vials

1 x 100 vials

1 x 150 vials

Not all pack sizes may be marketed.

Marketing Authorisation Holder:

Accord Healthcare Ireland Limited

Euro House

Euro Business Park

Little Island

Cork T45 K857

Ireland

Manufacturer:

Accord Healthcare Polska Sp.z o.o.

ul. Lutomska 50,

95-200 Pabianice, Poland

Or

Laboratori Fundació Dau

C/ C, 12-14 Pol. Ind.

Zona Franca, Barcelona, 08040,

Spain

Or

Pharmadox Healthcare Limited

KW20A Kordin Industrial Park, Paola

PLA 3000, Malta

This medicinal product is authorized in the Member States of the EEA under the following names:

Name of the member state	Name of the medicinal product
Austria	Dexamethason Accord 4 mg/ml injektions-/infusionslösung
Belgium	Dexamethasone Accord 4 mg/ml oplossing voor injectie/ infusie
Bulgaria	Дексаметазон фосфат Акорд 4 mg/ml инжекционен/ инфузионен разтвор
Cyprus	Dexamethasone phosphate Accord 4 mg/ml διάλυμα για ένεση/έγχυση
Croatia	Deksametazon Accord 4 mg/ml otopina za injekciju/infuziju
Denmark	Dexamethasone phosphate Accord
Finland	Inandex 4 mg/ml injektio-/infusioneste, liuos
Germany	Dexamethason Accord 4 mg/ml Injektions-/Infusionslösung
Hungary	Dexametazon-foszfát Accord 4 mg/ml oldatos injekció/infúzió
Iceland	Dexamethasone phosphate Accord
Ireland	Dexamethasone phosphate Accord 4 mg/ml solution for injection/infusion
The Netherland	Dexamethasonfosfaat Accord 4 mg/ml oplossing voor injectie/infusie
Norway	Dexamethasone phosphate Accord
Poland	Deksametazon Accord
Portugal	Dexametasona Accord
Spain	Dexametasona Accord 4 mg/ml solución inyectable y para perfusión EFG
Slovenia	Deksametazon Accord 4 mg/ml raztopina za injiciranje/infundiranje
Sweden	Inandex

This leaflet was last revised in {05/2024}.